Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

Dr Wendy Osborne of Newcastle upon Tyne Hospitals NHS Foundation Trust discusses AUTO3 data, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory DLBCL patients, presented during the American Society of Clinical Oncology (ASCO) Annual Meeting – courtesy of the Lymphoma Hub.

Find out more

Stock quote



Autolus Corporate Presentation – May 2021